Insmed Inc at JPMorgan Healthcare Conference Transcript
Great. Welcome, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're delighted to be continuing the 44th Annual Healthcare Conference today with Insmed. First, you're going to hear a presentation from the management team, and then we're going to go into some Q&A.
(Conference Instructions) So with that, let me pass it over to the company CEO, Will Lewis.
Thank you. Thanks, Jess, and thanks, everyone, for joining us today. I want to start out the presentation with the call out to our forward-looking statements. The forward-looking statements mentioned here in our public filings should be something that everyone reviews carefully. Before I begin the presentation, I'd like to take a moment to talk about what drives us at Insmed, and that is our impact on patients and to highlight that I'm going to read a quote from a physician that we recently got in regards to the BRINSUPRI product that is now on the market
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
